Current Rheumatology Reports

, 15:318

Duration of Anticoagulation Treatment for Thrombosis in APS: Is It Ever Safe to Stop?

ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)

DOI: 10.1007/s11926-013-0318-2

Cite this article as:
Punnialingam, S. & Khamashta, M.A. Curr Rheumatol Rep (2013) 15: 318. doi:10.1007/s11926-013-0318-2
Part of the following topical collections:
  1. Topical Collection on Antiphospholipid Syndrome

Abstract

Antiphospholipid syndrome (APS) is an auto-immune thrombophilia for which anti-thrombotic medication is necessary for long-term management to reduce thrombotic risk or pregnancy morbidity. Choosing the type of pharmacological treatment, i.e. the intensity and duration of anticoagulation, depends on the severity of an individual’s APS and the risk of bleeding. This article reviews the current literature on anticoagulation therapy, provides recommendations on when to initiate therapy, and suggests possible alternatives for optimisation of management.

Keywords

Antiphospholipid syndrome (APS)Antiphospholipid (aPL)Systemic lupus erythematosus (SLE)Anticoagulation therapyIntensityDurationThromboprophylaxisRefractory APSThrombosis

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of General MedicineGuy’s and St Thomas’ HospitalLondonUK
  2. 2.Graham Hughes Lupus Research Laboratory, Rayne InstituteSt Thomas’ HospitalLondonUK